An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Someone asked a technical question comparing two new weight-loss drugs and why they seem different in how strongly they curb appetite. The question notes both drugs act on two of the same hormone switches (called GIP and GLP‑1) and that one drug, retatrutide, also targets a third switch (glucagon). The asker wants to know the exact makeup — how much of each hormone-mimic is in each drug — because people report different effects in real life. Both drugs are synthetic peptides, which just means they’re small protein-like molecules made to copy natural hormones. Tirzepatide (sold as Zepbound/Zepzelca in some contexts) is designed to activate two receptors: GIP and GLP‑1. Those receptors are part of the body’s system for controlling appetite and blood sugar. Retatrutide is a newer triple-acting peptide that targets the same two receptors plus the glucagon receptor. Glucagon, unlike insulin, tends to raise blood sugar and increase energy use; when combined carefully with the other two effects it may boost weight loss. Saying a drug “includes GIP and GLP‑1 agonists” means it mimics those natural hormones so the body thinks they are present. What the question really asks — the exact percentage or ratio of GIP versus GLP‑1 activity inside each drug — isn’t something you can get from a bottle label. Clinical papers and company disclosures sometimes describe how strongly a drug activates each receptor in lab tests, but they don’t usually give a simple percentage split the way a recipe would. For tirzepatide, published studies and regulatory documents describe it as a single molecule with activity at both GIP and GLP‑1 receptors; authors report relative potency and dose–response from experiments, and clinical trials show it produces substantial appetite suppression and weight loss in humans. For retatrutide, early trial results reported big weight-loss numbers too, and the extra glucagon action is thought to increase energy burn. But direct, side‑by‑side molecular “percentages” available to the public aren’t usually provided, and most reports are either lab-focused or based on early human studies with limited participants. Why this matters: people curious about how these drugs work want to know why one feels stronger than another. If you’re considering one of these medications for weight loss or diabetes, understanding which receptors are targeted helps explain differences in appetite, energy, and side effects. Clinicians and researchers use that receptor information to predict outcomes and tailor treatments. But for a typical person, the practical takeaways are based more on clinical trial results and a doctor’s guidance than on microscopic ratios you can’t measure at home. Caveats and risks: don’t assume anecdotal reports reflect the full picture. Individual response varies a lot. Both drugs can cause nausea, gastrointestinal upset, and other side effects; adding glucagon activity may change side-effect profiles and effects on blood sugar. Regulatory status matters — tirzepatide has been approved for weight management in some places, while retatrutide is newer and may still be in trials. Only a healthcare provider can advise whether a specific drug is appropriate. There’s also limited public data comparing them directly in large head-to-head studies, so firm conclusions about “which is stronger” aren’t settled. Bottom line: both drugs act on similar appetite and metabolism switches, but public information doesn’t present their GIP vs. GLP‑1 makeup as a clean percentage, and real-world differences come from complex pharmacology and clinical trial results rather than a simple formula.
Source: r/Peptides